CD44v6并非原发性乳腺癌的预后因素。
CD44v6 is not a prognostic factor in primary breast cancer.
作者信息
Jansen R H, Joosten-Achjanie S R, Arends J W, Volovics A, Hupperets P S, Schouten H C, Hillen H F
机构信息
Department of Internal Medicine, University Hospital Maastricht, The Netherlands.
出版信息
Ann Oncol. 1998 Jan;9(1):109-11. doi: 10.1023/a:1008220917687.
BACKGROUND
CD44 is an adhesion molecule and represents a highly variable family of isoforms. The isoform CD44v6 has been associated with metastasis formation and poor prognosis in animal models and human colon cancer. Results of studies in primary breast cancer are relatively small and contradictory.
PATIENTS AND METHODS
The immunohistochemical expression of CD44v6 was studied in a series of 338 patients with primary breast tumours, uniformly staged and treated in a single center with a long median follow-up of 128 months. The prognostic significance of CD44v6 as well as the correlation with several clinicopathological features were analysed.
RESULTS
Two hundred nineteen of 338 (64.8%) of the breast cancer were CD44v6-positive (> 5% of tumour cells with positive staining). CD44v6 expression had no value for prognosticating disease-free or overall survival at this or any other cut-off point.
CONCLUSION
CD44v6 expression is not a prognostic factor in primary breast cancer.
背景
CD44是一种黏附分子，代表一个高度可变的异构体家族。异构体CD44v6在动物模型和人类结肠癌中与转移形成及不良预后相关。原发性乳腺癌的研究结果相对较少且相互矛盾。
患者与方法
对338例原发性乳腺肿瘤患者进行了CD44v6的免疫组化表达研究，这些患者在单一中心进行统一分期和治疗，中位随访期长达128个月。分析了CD44v6的预后意义以及与多种临床病理特征的相关性。
结果
338例乳腺癌患者中有219例（64.8%）CD44v6呈阳性（>5%的肿瘤细胞染色阳性）。在该切点或任何其他切点，CD44v6表达对无病生存期或总生存期的预后判断均无价值。
结论
CD44v6表达不是原发性乳腺癌的预后因素。
Zotero 插件